New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
20:25 EDTAER, AER, LOJN, LOJN, RCPT, RCPT, TOUR, TOUR, OCIP, OCIP, CST, CST, FLO, FLO, KATE, KATE, VAL, VAL, TW, TW, CVG, CVGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include AerCap Holdings (AER), consensus 77c; Towers Watson (TW), consensus $1.25; Valspar (VAL), consensus $1.13; Kate Spade (KATE), consensus 0c; Flowers Foods (FLO), consensus 24c; CST Brands (CST), consensus 49c; OCI Partners (OCIP), consensus 64c; Tuniu (TOUR), consensus (21c); Receptos (RCPT), consensus (85c); LoJack (LOJN), one estimate 4c; Convergys (CVG), consensus 32c.
News For AER;TW;VAL;KATE;FLO;CST;OCIP;TOUR;RCPT;LOJN;CVG From The Last 14 Days
Check below for free stories on AER;TW;VAL;KATE;FLO;CST;OCIP;TOUR;RCPT;LOJN;CVG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
09:33 EDTTWTowers Watson sees FY15 adjusted EPS $5.80-$5.95, consensus $5.90
Subscribe for More Information
09:30 EDTTWTowers Watson repeats view of Q1 adjusted EPS $1.17-$1.22, consensus $1.21
Repeats previously issued Q1 revenue view of $840M-$860M, consensus $850.03M. Sees Q1 EBITDA margin to be "around 18%."
09:29 EDTTWTowers Watson sees FY15 adjusted EPS $5.80-$5.95, consensus $5.90
Guidance from slides for analyst day meeting.
September 17, 2014
10:00 EDTKATEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:17 EDTKATEKate Spade initiated with a Buy at Wunderlich
Target $36.
September 16, 2014
07:46 EDTTWTowers Watson to host analyst day
Analyst Day to be held on September 19 at 10 am. Webcast Link
September 15, 2014
15:04 EDTLOJNLoJack SCI and Contguard form cargo container security alliance
Subscribe for More Information
12:02 EDTRCPTReceptos price target raised to $80 from $63 at Wedbush
Subscribe for More Information
10:59 EDTRCPTReceptos price target raised to $77 from $60 at Leerink
Subscribe for More Information
07:48 EDTRCPTReceptos price target raised to $75 from $58 at Credit Suisse
Credit Suisse raised Receptos' price target to $75 citing increased clarity on RPC1063's potential differentiated profile following presentation of further RADIANCE Ph II data. Share are Outperform rated.
September 12, 2014
10:00 EDTOCIPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Cedar Realty Trust (CDR) upgraded to Buy from Hold at KeyBanc... E.ON AG (EONGY) upgraded to Overweight from Neutral at JPMorgan... Genuine Parts (GPC) upgraded to Buy from Hold at BB&T... Inland Real Estate (IRC) upgraded at KeyBanc... Littelfuse (LFUS) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Equal Weight from Underweight at Barclays... Noranda Aluminum (NOR) upgraded to Buy from Neutral at Goldman... OCI Partners (OCIP) upgraded to Buy from Neutral at Citigroup... Ramco-Gershenson (RPT) upgraded at KeyBanc... Sprint (S) upgraded to Outperform from Market Perform at Cowen... T-Mobile (TMUS) upgraded to Buy from Hold at Argus... The Advisory Board (ABCO) upgraded to Outperform at Wells Fargo.
06:14 EDTOCIPOCI Partners upgraded to Buy from Neutral at Citigroup
Citigroup upgraded OCI Partners to Buy after assuming coverage of the stock and raised its price target for shares to $23 from $20. Citi sees a strong distribution growth profile for OCI in the coming years due to increases in methanol and ammonia capacity as well as the potential for a 35% drop-down driven distribution growth in 2017.
September 10, 2014
16:19 EDTRCPTOn The Fly: Closing Wrap
Subscribe for More Information
15:05 EDTRCPTReceptos surges after abstracts for RADIANCE trial posted
Shares of drugmaker Receptos (RCPT) are sharply higher after an abstract for the company's Phase 2 portion of its RADIANCE trial of RPC1063 in Relapsing Multiple Sclerosis, or RMS, were posted to the site of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS. WHAT'S NEW: This morning, Receptos announced that data from the Phase 2 portion of RADIANCE, the company's Phase 2/3 trial of RPC1063 in RMS, will be reviewed in a late breaker oral podium presentation at MS Boston on September 13. MS Boston is a joint meeting of ECTRIMS and ACTRIMS, which is the U.S. and Canadian counterpart to ECTRIMS. ANALYST REACTION: Analysts at BMO Capital said the RADIANCE data confirm differentiation of the drug. The firm has an Outperform rating and $72 price target on the stock. Meanwhile, Leerink said that the full RADIANCE data shows a 53% annualized relapse reduction and supports a "highly differentiated safety profile" for the drug. Leerink has an Outperform rating and $60 price target on shares of Receptos. PRICE ACTION: In late afternoon trading, shares of Receptos were up $11.29, or 24%, to $58.34.
12:50 EDTRCPTReceptos to host conference call
Subscribe for More Information
September 8, 2014
09:27 EDTRCPTLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use